Monoclonal antibody conjugated Nanoparticles targeted to Prostate tumor cells

Novel approaches to drug delivery and formulation using nanotechnology are revolutionizing the future of medicine. The application of nanotechnology in medicine is offering many exciting possibilities in healthcare. Engineered nanoparticles and conjugation of monoclonal antibodies with anticancer drug Docetaxel have the potential to revolutionize the diagnosis and the therapy of its diseases, particularly by targeted delivery of anticancer drugs and imaging contrast agents. Prostate cancer, the second most common cancer in men, represents one of the major epidemiological problems, especially for patients in the advanced age. There is a substantial interest in developing therapeutic options for treatment of prostate cancer based on use of nanocarriers with the conjugation of drug and antibody, to overcome the lack of specificity of conventional chemotherapeutic agents as well as for the early detection of precancerous and malignant lesions. In this article, we highlight on the recent development of bioconjugation of drug with nanotechnology strategies adopted for the management of prostate cancer. In particular, the combination of targeted and controlled-release polymer nanocarriers have worked against prostate specific membrane antigen, a promising targeted Docetaxel-loaded nanoparticles, which can be validated for use in the prostate cancer therapy. However, several limitations facing nanoparticle delivery to solid tumors, such as heterogeneity of intratumoural barriers and vasculature, cytotoxicity and or hypersensitivity reactions to currently available cancer nanomedicines, and the difficult in developing targeted nanoparticles with optimal biophysicochemical properties, should be still addressed for successful tumor eradication.